Morgan Stanley Alvotech Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALVO
# of Institutions
32Shares Held
15.5MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA3.17MShares$38.4 Million0.0% of portfolio
-
Bracebridge Capital, LLC2.71MShares$32.8 Million28.94% of portfolio
-
Howard Marks Oaktree Capital Management LP | Los Angeles, Ca2.53MShares$30.7 Million0.64% of portfolio
-
Littlejohn & CO LLC1.32MShares$16 Million6.38% of portfolio
-
Legal & General Group PLC London, X0997KShares$12.1 Million0.0% of portfolio
About Alvotech
- Ticker ALVO
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 248,650,000
- Market Cap $3.01B
- Description
- Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory condi...